Lucintel Forecasts Regenerative Medicine Market to Reach $10.2 billion by 2030

A recent study projects that the regenerative medicine market is set to grow to approximately $10.2 billion by 2030 from $8.2 billion in 2023, with a 3.0% Compound Annual Growth Rate (CAGR) from 2024 to 2030. The market’s growth is fueled by the increasing demand for personalized medicines, higher investments in research and development by governments and private organizations, and advancements in stem-cell therapies.

The report contains 94 figures/charts and 87 tables across 184 pages, providing insights into the trends, opportunities, and forecasts in the regenerative medicine market by material type (synthetic, biologically derived, genetically engineered), product category (cell-based immunotherapy, tissue-engineered products), application (musculoskeletal disorders, wound care), distribution channel (hospitals, clinics), and region.

Lucintel predicts that cell-based immunology and cell therapy products will continue to dominate the market due to increased government support for research and development activities and the FDA’s introduction of the Cures Act to streamline regenerative medicine approvals. Musculoskeletal disorders are expected to be the largest application segment, driven by the rise in orthopedic diseases and the aging population.

North America is anticipated to remain the largest region in the market, benefiting from advanced technologies and a significant number of research institutes focusing on developing new therapeutics. Key suppliers in the regenerative medicine market include Kite Pharma, Novartis, Vericel, and others.

For detailed information, contact Lucintel at +1-972-636-5056 or helpdesk@lucintel.com. Lucintel is a Dallas-based market research and consulting firm that provides growth solutions and analysis of market needs. Contact Roy Almaguer at roy.almaguer@lucintel.com or +1 972.636.5056 for more information.